Integer Holdings (ITGR) Could Be 12% Overvalued Following The KKR Bid
Integer Holdings (ITGR) agreed to be acquired by KKR in an all-cash deal valuing the company at about $5.7B. The offer is $127 per share. ITGR shares closed at $125.27 and have risen sharply since the bid. Simply Wall St cites a fair value of $112.14 (consensus target) and notes a DCF fair value of $169.74, with analyst targets ranging $95 to $127.
How this was made
The 30-second read
Why it matters
For traders, the key actionable element is the $127/share all-cash deal price, which typically anchors deal-arbitrage pricing. The article’s additional detail about conflicting fair-value estimates ($112.14 narrative vs $169.74 DCF) suggests uncertainty in how much upside/downside remains versus the bid, which can affect spread behavior and hedging decisions.
Market read
Deal terms provide a concrete reference price, while valuation-model disagreement and cited business risks imply potential volatility in deal-spread pricing.
What to watch
The article cites customer concentration and FX swings as risks, but does not quantify them; those could matter for deal closing probability and for how much of the valuation debate is actually relevant to arb pricing.
Background
The article frames Integer Holdings’ valuation around a pending KKR all-cash acquisition and contrasts multiple fair-value approaches.
Ticker impact
Integer Holdings agreed to be acquired by KKR in an all-cash deal valuing the company at about $5.7b, at $127 per share.
Near-term trading likely tracks deal-arb dynamics around the $127 reference price, with valuation debate affecting the probability-weighted outcome.
The text provides the deal consideration ($127/share) and deal-driven performance, then contrasts a narrative fair value of $112.14 versus a DCF fair value of $169.74, implying uncertainty in what the market should price in beyond the bid.
Market effects
A healthcare/medical-technology M&A headline can lift sentiment for adjacent med-tech deal-arb and valuation screens, though the article does not provide new sector fundamentals.
No specific regional market mechanism is described beyond US-listed deal pricing.
KKR’s bid may be read as continued global private-capital appetite for med-tech, but the article provides no cross-border regulatory or financing details.
Counterpoint
The stock’s move toward the $127 bid may already reflect deal certainty, so further upside may be limited unless deal terms improve or deal risk declines.
Key entities
- companyInteger Holdings
Subject of the acquisition offer, with deal price $127/share and mixed quarterly trends mentioned.
- acquirerKKR
Agreed to acquire Integer Holdings in an all-cash deal valuing it at about $5.7b.
